General MedicationsTOPICALGeneric
IMPEKLO
CLOBETASOL PROPIONATE
Standard Dose
0.05%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview IMPEKLO is listed in Drugs@FDA under application 213691 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient CLOBETASOL PROPIONATE Form and strength LOTION;TOPICAL - 0.05% Sponsor PHARMOBEDIENT Submission history Latest submission status date: 2020-05-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview IMPEKLO is listed in Drugs@FDA under application 213691 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CLOBETASOL PROPIONATE Form and strength LOTION;TOPICAL - 0.05% Sponsor PHARMOBEDIENT Submission history Latest submission status date: 2020-05-19 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.